In a filing, PMV Pharmaceuticals Inc revealed its 10% Owner ORBIMED ADVISORS LLC unloaded Company’s shares for reported $0.2 million on Nov 22 ’23. In the deal valued at $2.23 per share,87,786 shares were sold. As a result of this transaction, ORBIMED ADVISORS LLC now holds 0 shares worth roughly $0.0.
Then, Alland Leila sold 6,291 shares, generating $41,646 in total proceeds. Upon selling the shares at $6.62, the Chief Medical Officer now owns 45,909 shares.
Before that, Jalota Deepika sold 4,104 shares. PMV Pharmaceuticals Inc shares valued at $27,168 were divested by the Chief Development Officer at a price of $6.62 per share. As a result of the transaction, Jalota Deepika now holds 29,946 shares, worth roughly $51806.58.
Jefferies initiated its PMV Pharmaceuticals Inc [PMVP] rating to a Buy in a research note published on April 12, 2024; the price target was $5. A number of analysts have revised their coverage, including Ladenburg Thalmann’s analysts, who began to cover the stock in late December with a ‘”a Buy”‘ rating. Oppenheimer also remained covering PMVP and has increased its forecast on March 02, 2022 with a “an Outperform” recommendation from previously “Perform” rating. Goldman revised its rating on September 22, 2021. It rated PMVP as “a Buy” which previously was an “a Neutral”.
Price Performance Review of PMVP
On Monday, PMV Pharmaceuticals Inc [NASDAQ:PMVP] saw its stock jump 7.45% to $1.73. Over the last five days, the stock has gained 5.81%. PMV Pharmaceuticals Inc shares have fallen nearly -44.19% since the year began. Nevertheless, the stocks have fallen -63.81% over the past one year. While a 52-week high of $9.72 was reached on 01/02/24, a 52-week low of $1.17 was recorded on 02/14/24. SMA at 50 days reached $1.6866, while 200 days put it at $3.6034. A total of 0.54 million shares were traded, compared to the trading of 0.48 million shares in the previous session.
Levels Of Support And Resistance For PMVP Stock
The 24-hour chart illustrates a support level at 1.6350, which if violated will result in even more drops to 1.5400. On the upside, there is a resistance level at 1.7900. A further resistance level may holdings at 1.8500. The Relative Strength Index (RSI) on the 14-day chart is 54.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0301, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 27.27%. Stochastics %K at 48.05% indicates the stock is a holding.
The most recent change occurred on August 19, 2021 when Oppenheimer began covering the stock and recommended ‘”a Perform”‘ rating .
